Abstract
A class of potent, selective adenosine A3 receptor antagonists was obtained via optimisation of the screening hit N-[4-(4-methoxyphenyl)-thiazol-2-yl]-acetamide. Structural modifications of this hit revealed very quickly that a 5-(pyridin-4-yl) substituent on the 2- aminothiazole ring was optimal for high potency at the adenosine A3 receptor. Structure activity relationship studies led to both potent and selective A3 receptor antagonists, including N-[5-pyridin-4-yl-4-(3,4,5-trimethoxyphenyl)-thiazol-2-yl]-acetamide, a highly potent aden-osine A3 receptor antagonist with greater than 100- fold selectivity against the related adenosine receptors. As well as demonstrating selective in vitro binding on the human A3 adenosine receptor, this compound was also shown to selectively block the rat A3 receptor in vivo. This important new compound can be readily synthesised in four steps from commercially available starting materials.
Keywords: adenosine a3 receptor antagonists, n-[4-(4-methoxyphenyl)-thiazol-2-yl]-acetamide, n-[5-pyridin-4-yl-4-(3,4,5-trimethoxyphenyl)-thiazol-2-yl]-acetamide
Current Topics in Medicinal Chemistry
Title: New Highly Potent and Selective Adenosine A3 Receptor Antagonists
Volume: 4 Issue: 8
Author(s): Neil J. Press, Thomas H. Keller, Pamela Tranter, David Beer, Ken Jones, Alexander Faessler, Richard Heng, Christine Lewis, Trevor Howe and Peter Gedeck
Affiliation:
Keywords: adenosine a3 receptor antagonists, n-[4-(4-methoxyphenyl)-thiazol-2-yl]-acetamide, n-[5-pyridin-4-yl-4-(3,4,5-trimethoxyphenyl)-thiazol-2-yl]-acetamide
Abstract: A class of potent, selective adenosine A3 receptor antagonists was obtained via optimisation of the screening hit N-[4-(4-methoxyphenyl)-thiazol-2-yl]-acetamide. Structural modifications of this hit revealed very quickly that a 5-(pyridin-4-yl) substituent on the 2- aminothiazole ring was optimal for high potency at the adenosine A3 receptor. Structure activity relationship studies led to both potent and selective A3 receptor antagonists, including N-[5-pyridin-4-yl-4-(3,4,5-trimethoxyphenyl)-thiazol-2-yl]-acetamide, a highly potent aden-osine A3 receptor antagonist with greater than 100- fold selectivity against the related adenosine receptors. As well as demonstrating selective in vitro binding on the human A3 adenosine receptor, this compound was also shown to selectively block the rat A3 receptor in vivo. This important new compound can be readily synthesised in four steps from commercially available starting materials.
Export Options
About this article
Cite this article as:
Press J. Neil, Keller H. Thomas, Tranter Pamela, Beer David, Jones Ken, Faessler Alexander, Heng Richard, Lewis Christine, Howe Trevor and Gedeck Peter, New Highly Potent and Selective Adenosine A3 Receptor Antagonists, Current Topics in Medicinal Chemistry 2004; 4 (8) . https://dx.doi.org/10.2174/1568026043451023
DOI https://dx.doi.org/10.2174/1568026043451023 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Drugs for Epidural Analgesia
Current Drug Targets The Role of Oxidative Stress on Necrotizing Enterocolitis in Very Low Birth Weight Infants
Current Pediatric Reviews The Future of Interventional Management of Hypertension: Threats and Opportunities
Current Vascular Pharmacology Device-based Therapies for Resistant Hypertension
Current Pharmaceutical Design Impact of Ultrasound Contrast Agents in Echocardiographic Assessment of Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery Anesthetic-induced Myocardial Conditioning: Molecular Fundamentals and Scope
Current Medicinal Chemistry Microvascular Obstruction After Primary Percutaneous Coronary Intervention: Pathogenesis, Diagnosis and Prognostic Significance
Current Vascular Pharmacology Affinity Ligands for Industrial Protein Purification
Protein & Peptide Letters Therapeutic Potential of Nitrate Esters of Commonly Used Drugs
Current Topics in Medicinal Chemistry Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews Contrast Agents in X-Ray Computed Tomography and Its Applications in Oncology
Anti-Cancer Agents in Medicinal Chemistry Oxytocin in the Heart Regeneration
Recent Patents on Cardiovascular Drug Discovery Therapeutic Perspectives of Inhibitors of Endocannabinoid Degradation
Current Drug Targets - CNS & Neurological Disorders Hydrogen Sulfide Regulates Vascular Inflammation and its Related Signaling Pathways
Current Signal Transduction Therapy Towards the Development of Tumor Necrosis Factor (TNF) Sensitizers:Making TNF Work Against Cancer
Current Pharmaceutical Design Sugammadex, a Promising Reversal Drug. A Review of Clinical Trials
Reviews on Recent Clinical Trials Influence of the Bystander Effect on HSV-tk / GCV Gene Therapy. A Review.
Current Gene Therapy Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?
Current Drug Targets Nitric Oxide and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Pelvic Floor During Pregnancy and after Childbirth, and the Effect of Pelvic Floor Muscle Training on Urinary Incontinence - A Literature Review
Current Women`s Health Reviews